Gujarat Themis Biosyn Ltd. has commenced commercial production at its newly established Active Pharmaceutical Ingredient (API) manufacturing facility located at 69/C, GIDC Industrial Estate, Vapi – 396195, District Valsad, Gujarat, India.
The facility is designed as a multi-purpose plant capable of both synthetic and fermentation-based API production. It will manufacture a range of APIs and pharmaceutical intermediates intended for use in the pharmaceutical industry. This development is part of the company’s strategy to expand its manufacturing capabilities.
The new plant is expected to play a role in Gujarat Themis Biosyn’s forward integration efforts. It will also contribute to the company’s positioning in regulated export markets, including the United States and Europe.
Gujarat Themis Biosyn shares opened at ₹275.05 today, reaching a high of ₹276.45 and dipping to a low of ₹261.65. The stock remains below its 52-week high of ₹330.45 but well above the 52-week low of ₹208.00.
